Age-related macular degeneration

• Published in: Nature reviews. Disease primers Vol. 7; no. 1; p. 31
• Main Authors: Fleckenstein, Monika, Keenan, Tiarnán D. L., Guymer, Robyn H., Chakravarthy, Usha, Schmitz-Valckenberg, Steffen, Klaver, Caroline C., Wong, Wai T., Chew, Emily Y.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 06-05-2021; Nature Publishing Group
• Subjects: 692/1807/1482; 692/699/3161/1626; Age; Aging; Blindness - etiology; Cancer Research; Disease; Epidemiology; Grants; Health risk assessment; Humans; Internal Medicine; Macular degeneration; Macular Degeneration - diagnosis; Macular Degeneration - epidemiology; Medical Microbiology; Medicine; Medicine & Public Health; Oxidative Stress; Primer; Quality of life; Quality of Life Research; R&D; Research & development; Retina
• ISSN: 2056-676X; 2056-676X
• DOI: 10.1038/s41572-021-00265-2

Age-related macular degeneration (AMD) is the leading cause of legal blindness in the industrialized world. AMD is characterized by accumulation of extracellular deposits, namely drusen, along with progressive degeneration of photoreceptors and adjacent tissues. AMD is a multifactorial disease encompassing a complex interplay between ageing, environmental risk factors and genetic susceptibility. Chronic inflammation, lipid deposition, oxidative stress and impaired extracellular matrix maintenance are strongly implicated in AMD pathogenesis. However, the exact interactions of pathophysiological events that culminate in drusen formation and the associated degeneration processes remain to be elucidated. Despite tremendous advances in clinical care and in unravelling pathophysiological mechanisms, the unmet medical need related to AMD remains substantial. Although there have been major breakthroughs in the treatment of exudative AMD, no efficacious treatment is yet available to prevent progressive irreversible photoreceptor degeneration, which leads to central vision loss. Compelling progress in high-resolution retinal imaging has enabled refined phenotyping of AMD in vivo. These insights, in combination with clinicopathological and genetic correlations, have underscored the heterogeneity of AMD. Hence, our current understanding promotes the view that AMD represents a disease spectrum comprising distinct phenotypes with different mechanisms of pathogenesis. Hence, tailoring therapeutics to specific phenotypes and stages may, in the future, be the key to preventing irreversible vision loss.
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the developed world. This Primer describes the different stages of AMD, its epidemiology, the current understanding of its pathophysiology and diagnostic modalities. Additionally, it outlines existing treatment options and highlights the outstanding issues, suggesting future research avenues.